Sign up to access all valuation multiples
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company’s diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
1999
1.7K+
Last FY Revenue $140M
Last FY EBITDA $29.4M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Rubicon Research reported revenue of $140M and EBITDA of $29.4M.
Rubicon Research expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rubicon Research valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $140M | XXX | XXX | XXX |
| Gross Profit | XXX | $96.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 69% | XXX | XXX | XXX |
| EBITDA | XXX | $29.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 21% | XXX | XXX | XXX |
| EBIT | XXX | $24.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | 17% | XXX | XXX | XXX |
| Net Profit | XXX | $14.8M | XXX | XXX | XXX |
| Net Margin | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | $33.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rubicon Research has current market cap of INR 106B (or $1.2B), and EV of INR 110B (or $1.2B).
As of December 17, 2025, Rubicon Research's stock price is INR 642 (or $7).
See Rubicon Research trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialRubicon Research's trades at 8.7x EV/Revenue multiple, and 41.5x EV/EBITDA.
See valuation multiples for Rubicon Research and 15K+ public compsAs of December 17, 2025, Rubicon Research has market cap of $1.2B and EV of $1.2B.
Equity research analysts estimate Rubicon Research's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rubicon Research's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 41.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 50.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 78.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 124.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRubicon Research's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $44K for the same period.
Rubicon Research's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rubicon Research's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rubicon Research and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rubicon Research acquired XXX companies to date.
Last acquisition by Rubicon Research was XXXXXXXX, XXXXX XXXXX XXXXXX . Rubicon Research acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Rubicon Research founded? | Rubicon Research was founded in 1999. |
| Where is Rubicon Research headquartered? | Rubicon Research is headquartered in India. |
| How many employees does Rubicon Research have? | As of today, Rubicon Research has 1.7K+ employees. |
| Is Rubicon Research publicy listed? | Yes, Rubicon Research is a public company listed on NSE. |
| What is the stock symbol of Rubicon Research? | Rubicon Research trades under RUBICON ticker. |
| When did Rubicon Research go public? | Rubicon Research went public in 2025. |
| Who are competitors of Rubicon Research? | Similar companies to Rubicon Research include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Rubicon Research? | Rubicon Research's current market cap is $1.2B |
| Is Rubicon Research profitable? | Yes, Rubicon Research is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
